Ayten Eraydın
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ayten Eraydın has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Funda Datlı Yakaryılmaz
Inonu University Faculty of Medicine, Malatya, Turkey
2 shared publications - Semin Melahat Fenkci
Department of Endocrinology and Metabolism, Faculty of Medicine, Pamukkale University
2 shared publications - Asude Fenkci
School of Medicine, Yeditepe University, Istanbul, Türkiye
1 shared publication - Başak ÜNVER KOLUMAN
Pamukkale University, School of Medicine
1 shared publication Cihan Ilyas Sevgican
Denizli Saglik Hospital, Denizli, Turkey
1 shared publicationCihan İlyas Sevgican
Pamukkale Üniversitesi Tıp Fakültesi: Pamukkale Universitesi Tip Fakultesi
1 shared publication
Latest Publications
- Open Access
Association of SGLT2 Inhibitor Use with Glycosuria, Pyuria, Urinary Symptoms, and Significant Urine Culture Positivity in Adults with Type 2 Diabetes: A Prospective Cross-Sectional Study
Background and Objectives: Sodium–glucose cotransporter 2 (SGLT2) inhibitors increase urinary glucose excretion, but the relationship between glycosuria and findings supporting urinary tract infection (UTI) remains unclear. We evaluated associations of SGLT2 inhibitor use with glycosuria, pyuria, UTI-compatible symptoms, and significant urine culture positivity in adults with type 2 diabetes. Materials and Methods: This prospective cross-sectional study included 251 adults who reported using every agent in their current oral antidiabetic regimen for at least three months. Blood tests, urinalysis, and midstream urine culture were obtained at a single study visit. SGLT2 inhibitor users and nonusers were compared; contaminated cultures were excluded from culture-based analyses. Multivariable logistic regression examined factors associated with glycosuria and pyuria. Results: Overall, 108 participants (43.0%) used an SGLT2 inhibitor (dapagliflozin, n = 51; empagliflozin, n = 57). Glycosuria was more frequent among users than nonusers (69.4% vs. 39.9%; OR = 3.43; 95% CI, 2.02–5.82; p < 0.001). In multivariable analysis, SGLT2 inhibitor use (adjusted OR = 3.14; 95% CI, 1.75–5.63) and each 1% increase in HbA1c (adjusted OR = 1.56; 95% CI, 1.27–1.92) were independently associated with glycosuria. Pyuria and UTI-compatible symptoms did not differ between groups. Among 217 evaluable cultures, significant culture positivity was numerically higher among users, but the estimate was imprecise (9.5% vs. 4.1%; OR = 2.45; 95% CI, 0.79–7.57; p = 0.110). Symptomatic culture positivity was similar (4.2% vs. 4.1%; p = 1.000). Conclusions: SGLT2 inhibitor use and higher HbA1c levels were independently associated with glycosuria. The small number of culture-positive events precludes firm conclusions about culture-based outcomes; these analyses are exploratory and do not demonstrate the presence or absence of an association. Glycosuria alone should not be interpreted as an indicator of UTI.
Open AccessAssociation of SGLT2 Inhibitor Use with Glycosuria, Pyuria, Urinary Symptoms, and Significant Urine Culture Positivity in Adults with Type 2 Diabetes: A Prospective Cross-Sectional Study
Background and Objectives: Sodium–glucose cotransporter 2 (SGLT2) inhibitors increase urinary glucose excretion, but the relationship between glycosuria and findings supporting urinary tract infection (UTI) remains unclear. We evaluated associations of SGLT2 inhibitor use with glycosuria, pyuria, UTI-compatible symptoms, and significant urine culture positivity in adults with type 2 diabetes. Materials and Methods: This prospective cross-sectional study included 251 adults who reported using every agent in their current oral antidiabetic regimen for at least three months. Blood tests, urinalysis, and midstream urine culture were obtained at a single study visit. SGLT2 inhibitor users and nonusers were compared; contaminated cultures were excluded from culture-based analyses. Multivariable logistic regression examined factors associated with glycosuria and pyuria. Results: Overall, 108 participants (43.0%) used an SGLT2 inhibitor (dapagliflozin, n = 51; empagliflozin, n = 57). Glycosuria was more frequent among users than nonusers (69.4% vs. 39.9%; OR = 3.43; 95% CI, 2.02–5.82; p < 0.001). In multivariable analysis, SGLT2 inhibitor use (adjusted OR = 3.14; 95% CI, 1.75–5.63) and each 1% increase in HbA1c (adjusted OR = 1.56; 95% CI, 1.27–1.92) were independently associated with glycosuria. Pyuria and UTI-compatible symptoms did not differ between groups. Among 217 evaluable cultures, significant culture positivity was numerically higher among users, but the estimate was imprecise (9.5% vs. 4.1%; OR = 2.45; 95% CI, 0.79–7.57; p = 0.110). Symptomatic culture positivity was similar (4.2% vs. 4.1%; p = 1.000). Conclusions: SGLT2 inhibitor use and higher HbA1c levels were independently associated with glycosuria. The small number of culture-positive events precludes firm conclusions about culture-based outcomes; these analyses are exploratory and do not demonstrate the presence or absence of an association. Glycosuria alone should not be interpreted as an indicator of UTI.
- 1 September 2026
- Published by Bayrakol Medical Publishing in Eurasian Clinical and Analytical Medicine
- Vol. 14 (3) , 95-98
A rare case of thyroid metastasis occurring 27 years after initial diagnosis of breast cancer: A Case Report
Introduction Breast cancer (BC) most frequently metastasizes to bone, lung, and brain, whereas thyroid involvement is rare. We report a rare case of thyroid metastasis detected 27 years after the initial diagnosis of BC with subsequent pulmonary, cervical lymph node, and skeletal metastases. Case Presentation A 72-year-old woman diagnosed in 1997 with stage IIA, ER-positive, PR-positive, HER2-negative invasive ductal carcinoma underwent modified radical mastectomy followed by adjuvant therapy. After 27 disease-free years, a thyroid nodule was detected. Fine-needle aspiration suggested malignancy, and total thyroidectomy was performed. Immunohistochemistry showed GATA3, ER, and PR positivity with negative HER2, TTF-1, and thyroglobulin, confirming metastatic BC. PET-CT revealed cervical lymph node, pulmonary, and skeletal metastases. The patient received ribociclib, letrozole, and denosumab, with a favorable response at one-year follow-up. Conclusion This case highlights the importance of considering metastatic disease in newly detected thyroid nodules, even decades after the initial diagnosis of breast cancer.
- 1 September 2026
- Published by Bayrakol Medical Publishing in Eurasian Clinical and Analytical Medicine
- Vol. 14 (3) , 95-98
A rare case of thyroid metastasis occurring 27 years after initial diagnosis of breast cancer: A Case Report
Introduction Breast cancer (BC) most frequently metastasizes to bone, lung, and brain, whereas thyroid involvement is rare. We report a rare case of thyroid metastasis detected 27 years after the initial diagnosis of BC with subsequent pulmonary, cervical lymph node, and skeletal metastases. Case Presentation A 72-year-old woman diagnosed in 1997 with stage IIA, ER-positive, PR-positive, HER2-negative invasive ductal carcinoma underwent modified radical mastectomy followed by adjuvant therapy. After 27 disease-free years, a thyroid nodule was detected. Fine-needle aspiration suggested malignancy, and total thyroidectomy was performed. Immunohistochemistry showed GATA3, ER, and PR positivity with negative HER2, TTF-1, and thyroglobulin, confirming metastatic BC. PET-CT revealed cervical lymph node, pulmonary, and skeletal metastases. The patient received ribociclib, letrozole, and denosumab, with a favorable response at one-year follow-up. Conclusion This case highlights the importance of considering metastatic disease in newly detected thyroid nodules, even decades after the initial diagnosis of breast cancer.
- 26 June 2026
- Published by Elsevier in European Journal of Radiology
- Vol. 203, 113043
Superb microvascular imaging for evaluating the efficacy of microwave ablation in primary Hyperparathyroidism: A prospective study
- 26 June 2026
- Published by Elsevier in European Journal of Radiology
- Vol. 203, 113043
Superb microvascular imaging for evaluating the efficacy of microwave ablation in primary Hyperparathyroidism: A prospective study
- Open Access
- 16 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (12) , 4674
Polypharmacy Reflects Metabolic Burden Rather than Frailty in Older Adults with Type 2 Diabetes: A Comprehensive Geriatric Assessment Study
Background: Polypharmacy is highly prevalent among older adults with type 2 diabetes mellitus (T2DM) and is traditionally considered a marker of geriatric vulnerability. However, it remains unclear whether polypharmacy is more closely associated with multidimensional frailty or metabolic burden in this population. Methods: In this retrospective cross-sectional study, 278 adults aged ≥65 years with T2DM underwent comprehensive geriatric assessment (CGA), including evaluation of functional status, cognition, nutrition, depressive symptoms, frailty, and physical performance. Frailty was assessed using the Fried phenotype. Polypharmacy was defined as the concurrent use of ≥5 medications. Multivariable logistic regression and interaction analyses were performed to identify independent predictors of polypharmacy. Receiver operating characteristic (ROC) analyses were conducted to evaluate the discriminative performance of metabolic parameters. Results: Polypharmacy was present in 54.7% of participants. Patients with polypharmacy had significantly higher HbA1c and fasting glucose levels compared with those without polypharmacy (both p < 0.001). In multivariable analysis, higher HbA1c levels remained independently associated with polypharmacy (OR = 4.99, 95% CI: 3.18–7.84, p < 0.001), whereas frailty status was not significantly associated with polypharmacy (OR = 0.58, 95% CI: 0.15–2.21, p = 0.427). No significant interaction was observed between HbA1c and frailty status (p for interaction > 0.05). Among CGA domains, only functional status and gait speed differed in unadjusted analyses, while cognition, nutritional status, and depressive symptoms were not significantly associated with polypharmacy after adjustment. HbA1c demonstrated strong discriminative performance for polypharmacy (AUC = 0.898, 95% CI: 0.863–0.931), with an optimal cut-off of 6.81%. Conclusions: In older adults with T2DM, polypharmacy appeared to be more closely associated with markers of poor glycemic control, particularly HbA1c levels, than with frailty status itself. These findings suggest that medication burden in older adults with T2DM may reflect treatment intensification and suboptimal glycemic control in addition to geriatric vulnerability.
- 16 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (12) , 4674
Open AccessPolypharmacy Reflects Metabolic Burden Rather than Frailty in Older Adults with Type 2 Diabetes: A Comprehensive Geriatric Assessment Study
Background: Polypharmacy is highly prevalent among older adults with type 2 diabetes mellitus (T2DM) and is traditionally considered a marker of geriatric vulnerability. However, it remains unclear whether polypharmacy is more closely associated with multidimensional frailty or metabolic burden in this population. Methods: In this retrospective cross-sectional study, 278 adults aged ≥65 years with T2DM underwent comprehensive geriatric assessment (CGA), including evaluation of functional status, cognition, nutrition, depressive symptoms, frailty, and physical performance. Frailty was assessed using the Fried phenotype. Polypharmacy was defined as the concurrent use of ≥5 medications. Multivariable logistic regression and interaction analyses were performed to identify independent predictors of polypharmacy. Receiver operating characteristic (ROC) analyses were conducted to evaluate the discriminative performance of metabolic parameters. Results: Polypharmacy was present in 54.7% of participants. Patients with polypharmacy had significantly higher HbA1c and fasting glucose levels compared with those without polypharmacy (both p < 0.001). In multivariable analysis, higher HbA1c levels remained independently associated with polypharmacy (OR = 4.99, 95% CI: 3.18–7.84, p < 0.001), whereas frailty status was not significantly associated with polypharmacy (OR = 0.58, 95% CI: 0.15–2.21, p = 0.427). No significant interaction was observed between HbA1c and frailty status (p for interaction > 0.05). Among CGA domains, only functional status and gait speed differed in unadjusted analyses, while cognition, nutritional status, and depressive symptoms were not significantly associated with polypharmacy after adjustment. HbA1c demonstrated strong discriminative performance for polypharmacy (AUC = 0.898, 95% CI: 0.863–0.931), with an optimal cut-off of 6.81%. Conclusions: In older adults with T2DM, polypharmacy appeared to be more closely associated with markers of poor glycemic control, particularly HbA1c levels, than with frailty status itself. These findings suggest that medication burden in older adults with T2DM may reflect treatment intensification and suboptimal glycemic control in addition to geriatric vulnerability.
- Open Access
- 1 January 2025
- Published by Pamukkale University in Pamukkale Medical Journal
- Vol. 18 (4) , 15
Evaluation of PADI4 (Human Peptidyl Arginine Deiminase Type 4) levels in patients with type 2 diabetes mellitus with/without complications
Purpose: Human peptidyl arginine deiminase 4 (PADI4) transforms arginine residues on histone tails to citrulline. Recently, researchers have studied PADI4 in inflammation, infection, cancer, and autoimmune disorders. PADI4 also modulates the release of neutrophil extracellular traps (NETs) through a process known as NETosis, which is linked to dysglycemia. PADI4's role in type 2 diabetic mellitus (DM) is not well understood. The goal of this study is to compare PADI4 levels in type 2 DM patients who have not yet experienced diabetic complications, those who have, and a healthy control group. Materials and methods: This research included three groups of volunteers aged 30-65 years old: a healthy control group, a type 2 diabetic with no diabetic complications, and those with diabetic complications. Serum samples from control and type 2 DM patients were analyzed for complete blood count, biochemistry, and PADI4 (ng/ml). Results: The control, complicated, and uncomplicated type 2 DM groups did not differ significantly in their serum PADI4 levels (4.94±5.09 ng/ml (med: 2.62, IQR: 2.34-3.87), 5.06±6.58 ng/ml (med: 2.59, IQR: 2.19-2.99), and 4.51±4.76 (med: 2.74, IQR: 2.1- 3.71). Vitamin B12 levels were significantly higher in the complicated type 2 DM group than in the control group (647.83±461.37 vs. 357.32±136.15; p=0.03). The correlation analysis found no significant relationship between nephropathy, retinopathy, or neuropathy and serum PADI4 in the complicated type 2 DM group. There was a statistically significant, negative, and slight correlation with metformin use in the uncomplicated DM group (r=-0.325, p=0.05). Conclusion: Finally, there was no significant difference in serum PADI4 levels between the type 2 DM groups with complications, those without complications, and the healthy control group. PADI4 is seen as a viable target for illness treatment and surveillance. Prospective studies involving larger patient populations on this subject are needed.
- 1 January 2025
- Published by Pamukkale University in Pamukkale Medical Journal
- Vol. 18 (4) , 15
Open AccessEvaluation of PADI4 (Human Peptidyl Arginine Deiminase Type 4) levels in patients with type 2 diabetes mellitus with/without complications
Purpose: Human peptidyl arginine deiminase 4 (PADI4) transforms arginine residues on histone tails to citrulline. Recently, researchers have studied PADI4 in inflammation, infection, cancer, and autoimmune disorders. PADI4 also modulates the release of neutrophil extracellular traps (NETs) through a process known as NETosis, which is linked to dysglycemia. PADI4's role in type 2 diabetic mellitus (DM) is not well understood. The goal of this study is to compare PADI4 levels in type 2 DM patients who have not yet experienced diabetic complications, those who have, and a healthy control group. Materials and methods: This research included three groups of volunteers aged 30-65 years old: a healthy control group, a type 2 diabetic with no diabetic complications, and those with diabetic complications. Serum samples from control and type 2 DM patients were analyzed for complete blood count, biochemistry, and PADI4 (ng/ml). Results: The control, complicated, and uncomplicated type 2 DM groups did not differ significantly in their serum PADI4 levels (4.94±5.09 ng/ml (med: 2.62, IQR: 2.34-3.87), 5.06±6.58 ng/ml (med: 2.59, IQR: 2.19-2.99), and 4.51±4.76 (med: 2.74, IQR: 2.1- 3.71). Vitamin B12 levels were significantly higher in the complicated type 2 DM group than in the control group (647.83±461.37 vs. 357.32±136.15; p=0.03). The correlation analysis found no significant relationship between nephropathy, retinopathy, or neuropathy and serum PADI4 in the complicated type 2 DM group. There was a statistically significant, negative, and slight correlation with metformin use in the uncomplicated DM group (r=-0.325, p=0.05). Conclusion: Finally, there was no significant difference in serum PADI4 levels between the type 2 DM groups with complications, those without complications, and the healthy control group. PADI4 is seen as a viable target for illness treatment and surveillance. Prospective studies involving larger patient populations on this subject are needed.
- 19 April 2023
- Published by Springer Nature in Endocrine
- Vol. 81 (2) , 316-321
The effects of combination treatment with LT4 and LT3 on diastolic functions and atrial conduction time in LT4-treated women with low T3: a short term follow-up study
Purpose To investigate the effects of combination treatment with levothyroxine (LT4) and l- triiodothyronine (LT3) on left atrial volume (LAV), diastolic functions, and atrial electro-mechanical delays in LT4-treated women with low triiodothyronine (T3) levels. Methods This prospective study consisted of 47 female patients between 18 and 65 years old treated at an Endocrinology and Metabolism outpatient clinic between February and April 2022 due to primary hypothyroidism. The study included patients with persistently low T3 levels in at least three measurements, despite LT4 treatment (1.6–1.8 mcg/kg/m2) for 23.13 ± 6.28 months with normal thyrotropin (TSH) and free tetraiodothyronine (fT4) levels. The combination therapy dose was as follows: the fixed LT4 dose (25 mcg) was removed from patients’ usual LT4 treatment [100 mcg (min–max, 75–150)], and a fixed LT3 dose (12.5 mcg) was added. Biochemical samples were taken, and an echocardiographic assessment was performed for patients upon their first admission, and after 195.5 ± 12.8 days of receiving LT3 (12.5 mcg) treatment. Results There was a statistically significant reduction at left ventricle (LV) end-systolic diameter (27.69 ± 3.14, 27.13 ± 2.89, p = 0.035), left atrial (LA) maximum volume (14.73 ± 3.22, 13.94 ± 3.15, p = 0.009), LA minimum volume (7.84 ± 2.45, 6.84 ± 2.30, p < 0.001), LA vertical diameter (44.08 ± 6.92, 34.60 ± 4.31, p < 0.001), LAVI (50.73 ± 18.62, 41.0 ± 13.02, p < 0.001), total conduction time (103.69 ± 12.70, 79.82 ± 18.40, p < 0.001) after LT3 replacement (respectively pre-post- treatment and p value). Conclusion In conclusion, the findings of this study suggest that the addition of LT3 to LT4 treatment may lead to improvements in LAVI and atrial conduction times in patients with low T3. However, further research with larger patient groups and exploration of different LT4 + LT3 dose combinations is needed to better understand the effects of combined hypothyroidism treatment on cardiac functions.
- 19 April 2023
- Published by Springer Nature in Endocrine
- Vol. 81 (2) , 316-321
The effects of combination treatment with LT4 and LT3 on diastolic functions and atrial conduction time in LT4-treated women with low T3: a short term follow-up study
Purpose To investigate the effects of combination treatment with levothyroxine (LT4) and l- triiodothyronine (LT3) on left atrial volume (LAV), diastolic functions, and atrial electro-mechanical delays in LT4-treated women with low triiodothyronine (T3) levels. Methods This prospective study consisted of 47 female patients between 18 and 65 years old treated at an Endocrinology and Metabolism outpatient clinic between February and April 2022 due to primary hypothyroidism. The study included patients with persistently low T3 levels in at least three measurements, despite LT4 treatment (1.6–1.8 mcg/kg/m2) for 23.13 ± 6.28 months with normal thyrotropin (TSH) and free tetraiodothyronine (fT4) levels. The combination therapy dose was as follows: the fixed LT4 dose (25 mcg) was removed from patients’ usual LT4 treatment [100 mcg (min–max, 75–150)], and a fixed LT3 dose (12.5 mcg) was added. Biochemical samples were taken, and an echocardiographic assessment was performed for patients upon their first admission, and after 195.5 ± 12.8 days of receiving LT3 (12.5 mcg) treatment. Results There was a statistically significant reduction at left ventricle (LV) end-systolic diameter (27.69 ± 3.14, 27.13 ± 2.89, p = 0.035), left atrial (LA) maximum volume (14.73 ± 3.22, 13.94 ± 3.15, p = 0.009), LA minimum volume (7.84 ± 2.45, 6.84 ± 2.30, p < 0.001), LA vertical diameter (44.08 ± 6.92, 34.60 ± 4.31, p < 0.001), LAVI (50.73 ± 18.62, 41.0 ± 13.02, p < 0.001), total conduction time (103.69 ± 12.70, 79.82 ± 18.40, p < 0.001) after LT3 replacement (respectively pre-post- treatment and p value). Conclusion In conclusion, the findings of this study suggest that the addition of LT3 to LT4 treatment may lead to improvements in LAVI and atrial conduction times in patients with low T3. However, further research with larger patient groups and exploration of different LT4 + LT3 dose combinations is needed to better understand the effects of combined hypothyroidism treatment on cardiac functions.
- Open Access
- 11 January 2023
- Published by Springer Nature in Research Square
The Effects of Combination Treatment T4 and T3 on Diastolic Functions and Atrial Conduction Time in Women with Low T3: A short term Follow-up Study
Purpose To investigate the effects of combination thyroid replacement treatment on left atrial volume (LAV), diastolic functions, and atrial electromechanical delays in women with low triiodothyronine (T3) levels. Methods The study consisted of forty-seven female patients with primer hypothyroidism. The patients who had low T3 levels, despite using tetraiodothyronine (T4) treatment for a while with normal thyrotropin (TSH) and T4 levels with levothyroxine (LT4) treatment and started combination therapy were included in the study. Biochemical samples (TSH, free T4, free T3) were taken, and an echocardiographic assessment was performed for patients at first admission and after approximately six months of receiving T3 (12.5 mcg) treatment. Results There was a statistically significant reduction at left ventricle (LV) end-systolic diameter (27.69 ± 3.14, 27.13 ± 2.89, 0.035), left atrial (LA) maximum volume (14.73 ± 3.22, 13.94 ± 3.15, 0.009), LA minimum volume(7.84 ± 2.45, 6.84 ± 2.30, < 0.001), LA vertical diameter (44.08 ± 6.92, 34.60 ± 4.31, < 0.001), LA horizontal diameter (45.65 ± 6.88, 33.43 ± 4.51, < 0.001), LAVI (50.73 ± 18.62, 41.0 ± 13.02, < 0.001), total conduction time (103.69 ± 12.70, 79.82 ± 18.40, < 0.001) after T3 replacement (respectively pre-post treatment and p-value). Conclusion The results of the current study suggest that adding T3 to LT4 treatment may improve LAVI and atrial conduction times in patients with low T3. However, more research with larger patient groups is needed to better understand the effects of combined hypothyroidism treatment on cardiac functions.
- 11 January 2023
- Published by Springer Nature in Research Square
Open AccessThe Effects of Combination Treatment T4 and T3 on Diastolic Functions and Atrial Conduction Time in Women with Low T3: A short term Follow-up Study
Purpose To investigate the effects of combination thyroid replacement treatment on left atrial volume (LAV), diastolic functions, and atrial electromechanical delays in women with low triiodothyronine (T3) levels. Methods The study consisted of forty-seven female patients with primer hypothyroidism. The patients who had low T3 levels, despite using tetraiodothyronine (T4) treatment for a while with normal thyrotropin (TSH) and T4 levels with levothyroxine (LT4) treatment and started combination therapy were included in the study. Biochemical samples (TSH, free T4, free T3) were taken, and an echocardiographic assessment was performed for patients at first admission and after approximately six months of receiving T3 (12.5 mcg) treatment. Results There was a statistically significant reduction at left ventricle (LV) end-systolic diameter (27.69 ± 3.14, 27.13 ± 2.89, 0.035), left atrial (LA) maximum volume (14.73 ± 3.22, 13.94 ± 3.15, 0.009), LA minimum volume(7.84 ± 2.45, 6.84 ± 2.30, < 0.001), LA vertical diameter (44.08 ± 6.92, 34.60 ± 4.31, < 0.001), LA horizontal diameter (45.65 ± 6.88, 33.43 ± 4.51, < 0.001), LAVI (50.73 ± 18.62, 41.0 ± 13.02, < 0.001), total conduction time (103.69 ± 12.70, 79.82 ± 18.40, < 0.001) after T3 replacement (respectively pre-post treatment and p-value). Conclusion The results of the current study suggest that adding T3 to LT4 treatment may improve LAVI and atrial conduction times in patients with low T3. However, more research with larger patient groups is needed to better understand the effects of combined hypothyroidism treatment on cardiac functions.
- 22 June 2022
- Published by Galenos Yayinevi in Namık Kemal Tıp Dergisi
- Vol. 10 (2) , 199-205
Evaluation of the Relationship Between Polypharmacy and Malnutrition in Diabetic Elderly
- 22 June 2022
- Published by Galenos Yayinevi in Namık Kemal Tıp Dergisi
- Vol. 10 (2) , 199-205
Evaluation of the Relationship Between Polypharmacy and Malnutrition in Diabetic Elderly
- Open Access
- 1 January 2016
- Published by Turkiye Klinikleri in Turkiye Klinikleri Journal of Endocrinology
- Vol. 11 (1) , 10-14
Hypothyroidism in Pregnancy: Review
- 1 January 2016
- Published by Turkiye Klinikleri in Turkiye Klinikleri Journal of Endocrinology
- Vol. 11 (1) , 10-14
Open AccessHypothyroidism in Pregnancy: Review